Skip to main content

Atara Biotherapeutics, Inc. (ATRA) Stock Forecast

Data as of May 2, 2026

Healthcare · Current price $4.84 (+1.47%)

Consensus Target
$15.50
Upside
+220.3%
Analysts
3
Rating
Hold(3.33)

Price Target Range

Low $6.00Consensus $15.50High $25.00
▲ Current $4.84

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

No ratings in the last 3 months.
Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Nov 13, 2024Benjamin BurnettStifel Nicolaus$10.00+106.6%
Aug 16, 2024Salim SyedMizuho Securities$18.00+271.9%

ATRA vs Sector & Market

MetricATRAHealthcare AvgLarge Cap Avg
Analyst Rating3.332.242.41
Analyst Count3818
Target Upside+220.3%+1150.0%+14.9%
P/E Ratio1.556.8731.19

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$16M$16M$16M2
2027-12-31$51M$51M$51M3
2028-12-31$51M$51M$51M4
2029-12-31$91M$91M$91M3
2030-12-31$101M$101M$101M3

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$-0.69$-0.69$-0.692
2027-12-31$-0.78$-0.78$-0.782
2028-12-31$-2.35$-0.30$1.864
2029-12-31$2.24$2.24$2.242
2030-12-31$2.45$2.45$2.452

Frequently Asked Questions

What is the analyst consensus for ATRA?

The consensus among 3 analysts covering Atara Biotherapeutics, Inc. (ATRA) is Hold with an average price target of $15.50.

What is the highest price target for ATRA?

The highest price target for ATRA is $18.00, set by Salim Syed at Mizuho Securities on 2024-08-16.

What is the lowest price target for ATRA?

The lowest price target for ATRA is $10.00, set by Benjamin Burnett at Stifel Nicolaus on 2024-11-13.

How many analysts cover ATRA?

3 analysts have issued ratings for Atara Biotherapeutics, Inc. in the past 12 months.

Is ATRA a buy or sell right now?

Based on 3 analyst ratings, ATRA has a consensus rating of Hold (3.33/5) with a +220.3% upside to the consensus target of $15.50.

What are the earnings estimates for ATRA?

Analysts estimate ATRA will report EPS of $-0.69 for the period ending 2026-12-31, with revenue estimated at $16M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.